Author
Listed:
- Gayatri Amirthalingam
(Immunisation and Vaccine Preventable Diseases Division, UK Health Security Agency)
- Jamie Lopez Bernal
(Immunisation and Vaccine Preventable Diseases Division, UK Health Security Agency)
- Nick J. Andrews
(Immunisation and Vaccine Preventable Diseases Division, UK Health Security Agency)
- Heather Whitaker
(Statistics, Modelling and Economics Department, UK Health Security Agency)
- Charlotte Gower
(Immunisation and Vaccine Preventable Diseases Division, UK Health Security Agency)
- Julia Stowe
(Immunisation and Vaccine Preventable Diseases Division, UK Health Security Agency)
- Elise Tessier
(Immunisation and Vaccine Preventable Diseases Division, UK Health Security Agency)
- Sathyavani Subbarao
(Immunisation and Vaccine Preventable Diseases Division, UK Health Security Agency)
- Georgina Ireland
(Immunisation and Vaccine Preventable Diseases Division, UK Health Security Agency)
- Frances Baawuah
(Immunisation and Vaccine Preventable Diseases Division, UK Health Security Agency
Brondesbury Medical Centre, Kilburn)
- Ezra Linley
(Sero-Epidemiolgy Unit, UK Health Security Agency)
- Lenesha Warrener
(Virus Reference Department, UK Health Security Agency)
- Michelle O’Brien
(Brondesbury Medical Centre, Kilburn)
- Corinne Whillock
(Immunisation and Vaccine Preventable Diseases Division, UK Health Security Agency)
- Paul Moss
(University of Birmingham)
- Shamez N. Ladhani
(Immunisation and Vaccine Preventable Diseases Division, UK Health Security Agency
St. George’s University of London)
- Kevin E. Brown
(Immunisation and Vaccine Preventable Diseases Division, UK Health Security Agency)
- Mary E. Ramsay
(Immunisation and Vaccine Preventable Diseases Division, UK Health Security Agency)
Abstract
No abstract is available for this item.
Suggested Citation
Gayatri Amirthalingam & Jamie Lopez Bernal & Nick J. Andrews & Heather Whitaker & Charlotte Gower & Julia Stowe & Elise Tessier & Sathyavani Subbarao & Georgina Ireland & Frances Baawuah & Ezra Linley, 2022.
"Author Correction: Serological responses and vaccine effectiveness for extended COVID-19 vaccine schedules in England,"
Nature Communications, Nature, vol. 13(1), pages 1-1, December.
Handle:
RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-28393-7
DOI: 10.1038/s41467-022-28393-7
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-28393-7. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.